ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

IMM.GB Immupharma Plc

2.00
-0.55 (-21.57%)
28 Mar 2024 - Closed
Realtime Data
Share Name Share Symbol Market Type Share ISIN Share Description
Immupharma Plc AQSE:IMM.GB Aquis Stock Exchange Ordinary Share GB0033711010
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.55 -21.57% 2.00 1.50 2.50 2.55 2.00 2.55 464,916 16:29:58
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Immupharma PLC Holding(s) in Company (5484N)

26/10/2016 3:42pm

UK Regulatory


TIDMIMM

RNS Number : 5484N

Immupharma PLC

26 October 2016

 
 RNS : FOR IMMEDIATE RELEASE   26 OCTOBER 2016 
 

ImmuPharma PLC

("ImmuPharma" or the "Company")

TR1 NOTIFICATION OF MAJOR INTEREST

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that it has received a TR-1 by Lanstead Capital LP ("Lanstead"). Lanstead's holding in ImmuPharma is now confirmed at a total of 10,521,555 Ordinary Shares which equates to a current position in the Company of 8.4%.

Full disclosure of the TR1 is shown below:

-Ends-

 
 For further information please 
  contact: 
                                            + 44 (0) 20 
   ImmuPharma plc (www.immupharma.org)       7152 4080 
   Tim McCarthy, Chairman 
   Lisa Baderoon, Head of Investor 
    Relations                             + 44 (0) 7721 
    Twitter: @immupharma                   413496 
 
    Panmure, Gordon & Co., (NOMAD            +44 (0) 20 
    & Broker)                                7886 2500 
   Freddy Crossley, Duncan Monteith, 
    Corporate Finance 
    Charles Leigh-Pemberton, Corporate 
    Broking 
 
 
    Northland Capital Partners Limited 
    (Joint Broker) 
    Patrick Claridge, David Hignell, 
    Corporate Finance 
    Rob Rees, John Howes, Corporate        +44 (0)20 3861 
    Broking                                     6631 
 
 
 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i) 
-------------------------------------------------- 
 
 
 
 
 1. Identity of the issuer or                                             Immupharma plc 
  the underlying issuer 
  of existing shares to which 
  voting rights are 
  attached: (ii) 
-----------------------------------------------------------  --------------------------------------- 
 2 Reason for the notification (please tick the appropriate 
  box or boxes): 
---------------------------------------------------------------------------------------------------- 
 An acquisition or disposal of voting rights                                                       x 
------------------------------------------------------------------------------------------------ 
 An acquisition or disposal of qualifying financial 
  instruments which may result in the acquisition 
  of shares already issued to which voting rights 
  are attached 
------------------------------------------------------------------------------------------------ 
 An acquisition or disposal of instruments with 
  similar economic effect to qualifying financial 
  instruments 
------------------------------------------------------------------------------------------------ 
 An event changing the breakdown of voting rights 
------------------------------------------------------------------------------------------------ 
 Other (please                                               The placement by ImmuPharma PLC of    x 
  specify):                                                  2,857,143 new ordinary shares 
----------------------------------------------------------  ------------------------------------ 
 3. Full name of person(s)                                             Lanstead Capital LP 
  subject to the 
  notification obligation: 
  (iii) 
-----------------------------------------------------------  --------------------------------------- 
 4. Full name of shareholder(s) 
  (if different from 3.):(iv) 
-----------------------------------------------------------  --------------------------------------- 
 5. Date of the transaction                                              21 October 2016 
  and date on 
  which the threshold is 
  crossed or 
  reached: (v) 
-----------------------------------------------------------  --------------------------------------- 
 6. Date on which issuer                                                 25 October 2016 
  notified: 
-----------------------------------------------------------  --------------------------------------- 
 7. Threshold(s) that is/are 
  crossed or 
  reached: (vi, vii)                                               14%, 13%, 12%, 11%, 10%, 9% 
-----------------------------------------------------------  --------------------------------------- 
 
 
 
 8. Notified details: 
---------------------------------------------------------------------------------------------------------------------- 
 A: Voting rights attached to shares (viii, ix) 
---------------------------------------------------------------------------------------------------------------------- 
 Class/type     Situation previous                Resulting situation after the 
  of             to the triggering                 triggering transaction 
  shares         transaction 
 
  if possible 
  using 
  the ISIN 
  CODE 
-------------  --------------------------------  --------------------------------------------------------------------- 
                Number           Number           Number         Number of                    % of voting 
                 of               of               of shares      voting                       rights (x) 
                 Shares           Voting                          rights 
                                  Rights 
-------------  ---------------  ---------------  -------------  ---------------------------  ------------------------- 
                                                  Direct         Direct         Indirect      Direct        Indirect 
                                                                  (xi)           (xii) 
-------------      -----------    -----------    -------------  -------------  ------------  ------------  ----------- 
 GB0033711010   17,893,456       17,893,456       10,521,555     10,521,555                   8.44% 
               ---------------  ---------------  -------------  -------------  ------------  ------------  ----------- 
 
 
 B: Qualifying Financial Instruments 
---------------------------------------------------------------------------------------------------------------------- 
 Resulting situation after the triggering transaction 
---------------------------------------------------------------------------------------------------------------------- 
 Type of            Expiration     Exercise/                       Number of voting               % of voting 
 financial           date           Conversion                      rights that                    rights 
 instrument          (xiii)         Period (xiv)                    may be 
                                                                    acquired if 
                                                                    the 
                                                                    instrument 
                                                                    is 
                                                                    exercised/ 
                                                                    converted. 
-----------------  -------------  ------------------------------  -----------------------------  --------------------- 
       N/A 
-----------------  -------------  ------------------------------  -----------------------------  --------------------- 
 
 C: Financial Instruments with similar economic effect 
  to Qualifying Financial Instruments (xv, xvi) 
---------------------------------------------------------------------------------------------------------------------- 
 Resulting situation after the triggering transaction 
---------------------------------------------------------------------------------------------------------------------- 
 Type of          Exercise       Expiration     Exercise/        Number of voting               % of voting 
 financial         price         date           Conversion        rights instrument              rights (xix, 
 instrument                      (xvii)         period            refers to                      xx) 
                                                (xviii) 
---------------  -------------  -------------  ---------------  -----------------------------  ----------------------- 
      N/A                                                                                       Nominal       Delta 
---------------  -------------  -------------  ---------------  -----------------------------  ------------  --------- 
 
 
 Total (A+B+C) 
---------------------------------------------------------------------------------------------------------------------- 
 Number of voting rights                            Percentage of voting rights 
-------------------------------------------------  ------------------------------------------------------------------- 
 10,521,555                                         8.44% 
-------------------------------------------------  ------------------------------------------------------------------- 
 
 
 
 9. Chain of controlled undertakings through which the 
  voting rights and/or the 
  financial instruments are effectively held, if applicable: 
  (xxi) 
---------------------------------------------------------------------------------------- 
 
   N/A 
 
 Proxy Voting: 
---------------------------------------------------------------------------------------- 
 10. Name of the proxy holder: 
-------------------------------------------------------------  ------------------------- 
 11. Number of voting rights proxy 
  holder will cease to hold: 
-------------------------------------------------------------  ------------------------- 
 12. Date on which proxy holder will 
  cease to hold 
  voting rights: 
-------------------------------------------------------------  ------------------------- 
 
 
  13. Additional information: 
-------------------------------------------------------------  ------------------------- 
 14. Contact name:                                              Lisa De Vargas, Lanstead 
                                                                Partners Limited 
-------------------------------------------------------------  ------------------------- 
 15. Contact telephone number:                                  +1 (801) 895-3700 
-------------------------------------------------------------  ------------------------- 
 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

HOLZQLFLQBFXFBQ

(END) Dow Jones Newswires

October 26, 2016 10:42 ET (14:42 GMT)

1 Year Immupharma Chart

1 Year Immupharma Chart

1 Month Immupharma Chart

1 Month Immupharma Chart

Your Recent History

Delayed Upgrade Clock